BNET Industries
Last Fiscal Year Sales:$31.7M
- Public
- US
Dow Jones Description
Developer of Improvements to Medications for Pain & Attention Deficit Hyperactivity Disorder
Chief Executive Officer
David S. BarlowNumber of Employees 29
Peer Companies
NAICS Code Research and Development in the Social Sciences and Humanities: 541720
News & Analysis
Filter by
new river pharmaceuticals inc. - All News and Analysis
Healthcare stocks were hammered along with the rest of the market last week, although New River Pharmaceuticals Inc. closed Friday at $63.40Â?a new 52-week high
Medical Stock Spotlight: Healthcare stocks were hammered along with the rest of the market last week, although New River Pharmaceuticals Inc. Nasdaq closed Friday at $63.40--a new 52-week high. U.K.-based Shire PLC announced the week prior that it will buy New River for $2.6 billion. The FDA recently...
Shire and New River Pharmaceuticals Announce FDA Approval of the First and Only Stimulant Prodrug VYVANSE(TM) (lisdexamfetamine dimesylate) as a Novel Treatment for ADHD.
BASINGSTOKE, England, Philadelphia, PHILADELPHIA and Radford, VIRGINIA, February 23 /PRNewswire/ -- Shire plc (LSE: SHP, NASDAQ: SHPGY, TSX: SHQ) and its collaborative partner New River Pharmaceuticals Inc. (NASDAQ: NRPH) announced today that the BASINGSTOKE, England, Philadelphia, PHILADELPHIA and Radford, VIRGINIA, February...
Shire plc to Acquire New River Pharmaceuticals.
M2 PRESSWIRE-20 February 2007-Early Watch: Shire plc to Acquire New River PharmaceuticalsC1994-2007 M2 COMMUNICATIONS LTD RDATE:20022007 New River Pharmaceuticals Inc. (NASDAQ:NRPH) is a specialty pharmaceutical company developing novel pharmaceuticals that are generational improvements of widely prescribed drugs in large and ...
Trade Alert for New River Pharmaceuticals Inc.
M2 PRESSWIRE-20 February 2007-Biotech News: Trade Alert for New River Pharmaceuticals IncC1994-2007 M2 COMMUNICATIONS LTD RDATE:20022007 Trade Alert for New River Pharmaceuticals Inc (NASDAQ:NRPH) New River Pharmaceuticals isn't content to just go with the flow. The company is developing...
New River Pharmaceuticals and Shire Receive Approvable Letter for VYVANSE(TM) (lisdexamfetamine dimesylate) for the Treatment of ADHD.
BASINGSTOKE, England, PHILADELPHIA and RADFORD, Virginia, December 22 /PRNewswire/ -- - Launch Expected Q2 2007 New River Pharmaceuticals Inc. (Nasdaq: NRPH) and its collaborative partner Shire plc (LSE: SHP, Nasdaq: SHPGY, TSX: SHQ) announced today that the U.S. Food and Drug...
Bellwether Report.com Announces Alert for New River Pharmaceuticals Inc.
M2 PRESSWIRE-9 October 2006-bellwetherreport.com: Bellwether Report.com Announces Alert for New River Pharmaceuticals Inc.C1994-2006 M2 COMMUNICATIONS LTD RDATE:09102006 Bellwether Report Takes Notice of New River Pharmaceuticals Inc. (Nasdaq:NRPH) The company is developing improvements to existing medications for pain...
New River Pharmaceuticals Inc.
M2 PRESSWIRE-15 August 2006-bellwetherreport.com: New River Pharmaceuticals Inc.C1994-2006 M2 COMMUNICATIONS LTD RDATE:15082006 The Bellwether Report Takes Notice of New River Pharmaceuticals Inc. (Nasdaq:NRPH) New River Pharmaceuticals isn't content to just go with the flow. The company is developing...
AMRI Announces Long-Term Manufacturing Agreement with New River Pharmaceuticals
ALBANY, N.Y. -- Albany Molecular Research, Inc. (Nasdaq: AMRI) today announced a multi-year drug substance manufacturing agreement with New River Pharmaceuticals Inc. (Nasdaq: NRPH). Financial terms were not disclosed. Under the agreement, AMRI will manufacture the active pharmaceutical ingredient in New River's compound, NRP104, a new treatment for attention...
Shire Announces New River Pharmaceuticals Filing of NRP104.
PHILADELPHIA, Pennsylvania and BASINGSTOKE, England, December 7 /PRNewswire/ -- Shire plc (LSE: SHP, NASDAQ: SHPGY, TSX: SHQ) announced today that New River Pharmaceuticals, Inc. NRP has filed with the U.S. Food and Drug Administration FDA a PHILADELPHIA, Pennsylvania and BASINGSTOKE, England,...
New River Pharmaceuticals - Chmn., Pres. & CEO Interview
MARK HAINES, CNBC ANCHOR: The best-performing IPO of last year, it`s not Google GOOG, specialty pharma company New River Pharmaceuticals. Since going pubic exactly one year ago the stock up more than 300 percent, as you can see there, 350 versus Google, almost 200 percent....
- 1
- 2
Decision Makers
| Name (plus bio) | Position |
|---|---|
| David S. Barlow | Chief Executive Officer |
| John K. Thottathil | Chief Scientific Officer |
| Robert D Colucci | Vice President, Clinical Development |
| Peat Marwick | |
| Burton E. Sobel | Director |
Board of Directors
| Name (plus bio) | Position |
|---|---|
| Krish S. Krishnan | Board of Directors |
| Roger D. Griggs | Board of Directors |
David S. Barlow has served as a member of our board of directors since 2000. Since March 2000 Mr. Barlow has served as Chairman of Molecular Insight Pharmaceuticals, Inc., an emerging biopharmaceutical company focused on developing innovative molecular imaging pharmaceuticals and targeted radiotherapeutics for cancer, and as Chief Executive Officer since December 2002. From 1995 to September 1999, Mr. Barlow was President of Pharmaceuticals at Sepracor, Inc., a research-based pharmaceutical company. From 1993 to 1995, Mr. Barlow served as the General Manager of Pharmaceuticals at Sepracor, Inc. Prior to 1993, Mr. Barlow held several senior level positions at Rhone-Poulenc Rorer, Inc., pharmaceutical company, including Vice President, World Wide Marketing and Business Development at Armor Pharmaceutical Company, a subsidiary of Rhone-Poulenc Rorer, Inc. Mr. Barlow serves on the Board of Trustees of Bates College, McLean Hospital and Newton Country Day School.
| Organization | Position | Status |
|---|---|---|
| New River Pharmaceuticals, Inc. | Chief Executive Officer | Current |
| Bates College | Trustee | Current |
| Massachusetts General Hospital | Current | |
| Newton Country Day School | Board of Directors | Current |
| Molecular Insight Pharmaceuticals, Inc. | Board of Directors | Current |
| McLean Hospital | Board of Directors | Current |
| McLean Hospital | Trustee | Current |
| Molecular Insight Pharmaceuticals, Inc. | Chairman and Chief Executive Officer | Former |
| Novartis Oncology | Chief Executive Officer | Former |
| Sepracor Inc. | President | Former |
| Novartis Oncology | President | Former |
| Rhone-Poulenc Rorer | Vice President | Former |
| Sepracor Inc. | General Manager | Former |
| Pfizer Inc. | Former | |
| New River Pharmaceuticals, Inc. | Board of Directors | Former |
| Stanford University | M.B.A. | Former |
| Bates College | B.A. | Former |
| New River Pharmaceuticals, Inc. | Member | Former |
| Presidents Council | member | Former |
New River Pharmaceuticals Inc. welcomed Dr. Thottathil as its Chief Scientific Officer in April, 2006. Prior to joining New River, Dr. Thottathil served for over four years as the Director of Core Research and Development Chemistry, Diagnostic Division, at Abbott Laboratories. Prior to that, he worked at Bristol-Myers Squibb for 19 years in a variety of positions, most recently as Director of Outsourcing, Worldwide Process Research and Development, and earlier as Director of Chemical Process Research Departments in New Brunswick, NJ and Candiac, Canada. Several of his projects resulted in product launches; he has contributed to 60 patents, and has authored or co-authored more than 40 peer-reviewed publications.
| Organization | Position | Status |
|---|---|---|
| New River Pharmaceuticals, Inc. | Chief Scientific Officer | Current |
| Bristol-Myers Squibb Company | Former | |
| Abbott Laboratories | Former |
| Organization | Position | Status |
|---|---|---|
| New River Pharmaceuticals, Inc. | Vice President, Clinical Development | Current |
| Hartford Hospital | Former |
| Organization | Position | Status |
|---|---|---|
| New River Pharmaceuticals, Inc. | Current | |
| E.I. du Pont de Nemours & Company | Former | |
| University of Toledo | M.S. in Engineering | Former |
| Indian Institute of Technology | B.S. in Mechanical Engineering | Former |
| Organization | Position | Status |
|---|---|---|
| ARIAD Pharmaceuticals, Inc. | Board of Directors | Current |
| ARIAD Pharmaceuticals, Inc. | Board of Directors | Current |
| Nuvelo, Inc. | Board of Directors | Current |
| Clinical Data Inc. | Board of Directors | Current |
| New River Pharmaceuticals, Inc. | Director | Current |
| Barnes Hospital | Administrative | Former |
| University of Vermont | Professor | Former |
| Washington University School of Medicine | Administrative | Former |
| Peter Bent Brigham Hospital | Former | |
| University of Vermont | Chairman | Former |
| Harvard University | M.D. | Former |
| Cornell University | A.B. | Former |
| Organization | Position | Status |
|---|---|---|
| Third Security, LLC | Cfo and Coo | Current |
| Third Security, LLC | Senior Managing Director | Current |
| New River Pharmaceuticals, Inc. | Board of Directors | Current |
| Cyntellect, Inc. | Member of the Company's Board of Directors | Current |
| New River Inc. | Chief Financial Officer | Former |
| New River Pharmaceuticals, Inc. | Cfo, Coo & Secretary | Former |
| A.T. Kearney, Inc. | Senior Manager | Former |
| New River Pharmaceuticals, Inc. | Member | Former |
| Ariba, Inc. | Managing Principal | Former |
| University of Toledo | M.S. In Engineering | Former |
| Wharton Graduate School of the University of Pennsylvania | M.B.A. | Former |
| University of Pennsylvania | M.B.A. | Former |
| Indian Institute of Technology | B.S. In Mechanical Engineering | Former |
| Organization | Position | Status |
|---|---|---|
| Pediamed Pharmaceuticals, Inc. | Executive Chairman | Current |
| New River Pharmaceuticals, Inc. | Board of Directors | Current |
| Xanodyne Pharmaceuticals, Inc. | Chairman | Former |
| Indiana University | B.S. in Secondary Education | Former |
Industry Transcripts by Seeking Alpha
-
51jobs Q3 2009 Earnings Call Transcript
on Nov 23, 2009about JOBS
-
NetEase Q3 2009 Earnings Call Transcript
on Nov 18, 2009about NTES
-
Franklin Covey Co. F4Q09 (Qtr End 08/31/09) Earnings Call Transcript
on Nov 16, 2009about FC
-
Cellcom Israel Ltd. Q3 2009 Earnings Call Transcript
on Nov 16, 2009about CEL
-
URS Corporation Q3 2009 Earnings Call Transcript
on Nov 13, 2009about URS

